Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$10.96 +0.3%	$13.55	$7.05 ▼ $17.15	$286.92M	0.4	80,430 shs	71,260 shs
CMPS COMPASS Pathways	$4.34 -0.2%	$3.99	$2.25 ▼ $8.54	$406.99M	2.16	2.28 million shs	2.52 million shs
GOSS Gossamer Bio	$2.00 -2.0%	$1.41	$0.66 ▼ $2.18	$463.70M	1.95	2.78 million shs	2.69 million shs
ORMP Oramed Pharmaceuticals	$2.12 -1.4%	$2.18	$1.82 ▼ $3.09	$87.82M	1.61	67,113 shs	61,152 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	+0.27%	-1.97%	-13.97%	-27.18%	+24.26%
CMPS COMPASS Pathways	-0.23%	+0.23%	+28.40%	+3.58%	-43.12%
GOSS Gossamer Bio	-1.96%	+8.70%	+65.29%	+69.49%	+121.41%
ORMP Oramed Pharmaceuticals	-1.40%	-1.85%	-1.85%	-8.62%	-16.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.5867 of 5 stars	3.6	0.0	0.0	3.4	0.8	0.0
CMPS COMPASS Pathways	2.6028 of 5 stars	3.4	4.0	0.0	2.2	0.8	0.6
GOSS Gossamer Bio	3.9096 of 5 stars	3.5	1.0	4.7	3.8	1.7	0.0
ORMP Oramed Pharmaceuticals	0.7783 of 5 stars	0.0	3.0	0.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.13	Buy	$26.00	137.23% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	291.71% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	312.50% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, BNTC, GOSS, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	3,596.25	N/A	N/A	$4.68 per share	2.34
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GOSS Gossamer Bio	$114.70M	3.96	N/A	N/A	$0.13 per share	15.38
ORMP Oramed Pharmaceuticals	$1.34M	64.63	N/A	N/A	$3.61 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-85.64%	-59.63%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)

Latest ORMP, BNTC, GOSS, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	ORMP Oramed Pharmaceuticals	-$0.01	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
GOSS Gossamer Bio	6.70	5.71	5.71
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
GOSS Gossamer Bio	81.23%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
GOSS Gossamer Bio	6.70%
ORMP Oramed Pharmaceuticals	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable

ORMP, BNTC, GOSS, and CMPS Headlines

Recent News About These Companies

Zacks Small Cap Has Pessimistic Outlook of ORMP Q2 Earnings

August 2 at 2:09 AM | americanbankingnews.com

Zacks Small Cap Has Negative Outlook for ORMP Q2 Earnings

August 1 at 5:41 AM | marketbeat.com

With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio

July 29, 2025 | msn.com

BML Capital Management LLC Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

July 26, 2025 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below Two Hundred Day Moving Average - Here's Why

July 18, 2025 | marketbeat.com

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

February 11, 2025 | contractpharma.comC

OraTech to pioneer oral insulin with $75 million investment

February 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, BNTC, GOSS, and CMPS Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$10.96 +0.03 (+0.27%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.96 -0.01 (-0.05%)

As of 08/1/2025 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.34 -0.01 (-0.23%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.35 +0.01 (+0.23%)

As of 08/1/2025 07:38 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Gossamer Bio NASDAQ:GOSS

$2.00 -0.04 (-1.96%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/1/2025 07:07 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 -0.03 (-1.40%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.11 -0.01 (-0.47%)

As of 08/1/2025 04:10 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time